Clinicopathologic Characteristics and Prognostic Factors of Nonfunctioning Endocrine Tumor of the Pancreas.
- Author:
Soo Min PARK
1
;
Jin Young JANG
;
Mee Joo KANG
;
Yoo Seok YOON
;
Ho Seong HAN
;
Jai Young CHO
;
Seung Eun LEE
;
Kyoung Bun LEE
;
In Woong HAN
;
Sun Whe KIM
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Korea. jangjy4@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Neuroendocrine tumors;
Pancreas;
Prognosis;
Survival rate
- MeSH:
Body Weight;
Female;
Follow-Up Studies;
Humans;
Liver;
Lymph Nodes;
Male;
Neoplasm Metastasis;
Neuroendocrine Tumors;
Pancreas;
Pathology, Surgical;
Prognosis;
Recurrence;
Survival Rate
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2011;15(1):50-57
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Nonfunctioning endocrine tumors of the pancreas have no specific symptoms. Therefore, diagnosis is usually delayed and the malignancy rate at the time of diagnosis is reported to be higher than 50%. However, it is difficult to discriminate malignant from benign nonfunctioning endocrine tumors preoperatively. The purpose of this study was to investigate clinical characteristics of nonfunctioning endocrine tumors of the pancreas, including predictive factors of malignancy and prognostic factors affecting long-term survival. METHODS: Between 1992 and 2010, clinicopathological data of 53 patients with nonfunctioning endocrine tumors proven by surgical pathology were reviewed retrospectively. RESULTS: Of the 53 patients, mean age was 54 years-old and the male to female ratio was 1:1.2 Median follow up was 32.1 months. At the time of diagnosis, liver metastasis was detected in 4 patients. Curative resection was achieved in 49 patients, and 17% of them had recurrence, which was most common in liver. The overall 5-year survival rate was 85.1%. Both the WHO classification (p<0.001) and AJCC staging (p<0.001) correlated well with long-term survival. Univariate analysis revealed preoperative body weight loss (p<0.001), weak enhancement at the early arterial phase (p=0.043), lymph node metastasis (p<0.001), liver metastasis (p=0.001), perineural invasion (p=0.001), or lymphovascular invasion (p=0.010) as prognostic factors. CONCLUSION: Nonfunctioning endocrine tumor of the pancreas has favorable survival outcomes. Lymph node metastasis (p<0.001), liver metastasis (p=0.001), perineural invasion (p=0.001), and lymphovascular invasion (p=0.010) are poor prognostic factors.
